October 23, 2012
While Regeneron (Nasdaq: REGN ) doesn't rank among top performers in the Nasdaq Composite, its year-to-date performance is still nothing short of impressive. Shares have risen around 180% and boosted the company's market capitalization to nearly $15 billion on the strength of Eylea, the company's flagship drug targeting age-related macular degeneration. The company reports earnings Wednesday, and as is the case for many high flying-stocks, hitting Wall Street's revenue estimates and offering strong guidance for the future will play a vital role in which direction the shares go.
In the following video, health care bureau chief Brenton Flynn outlines the competitive environment for Regeneron's Eylea, including one low-priced drug that could turn out to be its biggest competition.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.